The usual intramuscular dose is between 1000 mcg and 2500 mcg per shot
The biomarker data, reported as exploratory endpoints in the published trial results, are where the outcome becomes genuinely instructive
BPC-157 influences angiogenesis and vascular repair, while TB-500 supports cell migration and tissue remodeling
Companies that successfully address muscle preservation, reduce discontinuation-related regain, improve access and tolerability, or develop precision approaches for treatment-resistant patients will capture meaningful differentiation in what promises to become an increasingly commoditized market for first-generation GLP-1 agonists
The underutilization of GLP-1 RAs presents an opportunity to improve outcomes in this high-risk population without increased complications
New real-world evidence suggests that staying on GLP-1 therapy may be critical for sustaining cardiovascular protection, while even short interruptions could diminish long-term benefits in people with type 2 diabetes
